From: The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
Clinical symptom
Before treatment
(n = 23)
After treatment
P valuea
Cough
22 (95.7)
16 (69.6)
0.0412
Sputum
12 (52.2)
0.0044
Dyspnea
15 (65.2)
14 (60.9)
>0.99
Hemoptysis
5 (21.7)
3 (13.0)
0.4795
Fever
1 (4.3)
0